Norgine, a European specialist pharmaceutical company, completed the acquisition of Azanta, a speciality biopharmaceutical company operating within women’s healthcare, addiction medicine and oncology, from European Equity Partners, a private investment firm focused on life science investments. Financial terms were not disclosed. "Our commitment to transforming people's lives drives everything we do and we are very proud to welcome the Azanta team and their portfolio of speciality products to Norgine. This transaction will enable us to strengthen our business in Europe and ultimately to help more patients," Peter Stein, Norgine CEO.